Imbria Pharmaceuticals: $57.5 Million (Series B) Raised To Develop Novel Therapies For Cardiometabolic Diseases
Summary
And the company plans to initiate FORTITUDE-HCM in Q2 2025, with topline data in late 2026.Ninerafaxstat previously showed positive results in multiple Phase 2a clinical trials in nHCM (the IMPROVE-HCM trial) and heart failure with preserved ejection fraction (HFpEF) (the IMPROVE-DiCE trial).The company also revealed the appointment of its current Executive Chair, Alvin Shih, MD, to the Chief Executive Officer role and the appointment of Rebecca Luse, Managing Director at Deep Track Capital, to its Board of Directors. He holds an MBA from the Kellogg School of Management, an MD from the University of Alabama, and completed his residency training in internal medicine at the Massachusetts General Hospital.Its a privilege to step into the role of CEO at such a defining moment for Imbria. The closing of this funding round, the initiation of our Phase 2b nHCM trial, and the recent presentation of our HFpEF data at ACC.25 all point to an exciting future for ninerafaxstat. Ninerafaxstats unique mechanism of action, coupled with a strong efficacy and safety profile that has now been demonstrated in multiple clinical trials, positions it as a potential first-in-class therapy for a broad spectrum of cardiometabolic diseases with high unmet need.We eagerly look forward to the outcome of the FORTITUDE-HCM trial which we believe will confirm the efficacy of ninerafaxstat in improving quality of life and functional capacity of patients with nHCM, who currently have no approved therapeutic options. We believe in the potential of ninerafaxstat to provide a novel and differentiated treatment for nHCM and other cardiometabolic diseases, and we are proud to support the Imbria team under Dr. Shihs leadership at this pivotal juncture.